Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Antag Therapeutics has initiated a first-in-human, double-blind Phase Ia trial of the glucose-dependent insulinotropic ...

Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in ...

A survey reveals that older adults strongly support Medicare coverage for weight management medications, but few are willing ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

RANI READ THE FULL RANI RESEARCH REPORT On March 31 st , Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported 2024 results. Since the third quarter report, Rani has participated in multiple ...

Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and ...

Cash, cash equivalents and marketable securities as of December 31, 2024 totaled $27.6M, compared to $48.5M for the year ended December 31, ...

Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® ...

As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks ...